Jourde-Chiche N, Costedoat-Chalumeau N, Baumstarck K et al. Weaning of maintenance immunosuppressive therapy in lupus nephritis (WIN-Lupus): results of a multicentre randomised controlled trial. Ann Rheum Dis. 2022 Oct;81(10):1420-1427.
Kaul A, Gordon C, Crow MK et al. Systemic lupus erythematosus. Nat Rev Dis Primers. 2016 Jun 16;2:16039.
Bajema IM, Wilhelmus S, Alpers CE et al. Revision of the International Society of Nephrology/Renal Pathology Society classification for lupus nephritis: clarification of definitions, and modified National Institutes of Health activity and chronicity indices. Kidney Int. 2018 Apr;93(4):789-796.
Fanouriakis A, Tziolos N, Bertsias G et al. Update οn the diagnosis and management of systemic lupus erythematosus. Ann Rheum Dis. 2021 Jan;80(1):14-25.
Dai Z, Zhang X, Wong IO et al. Treatment for Severe Lupus Nephritis: A Cost-Effectiveness Analysis in China. Front Pharmacol. 2021 Sep 6;12:678301.
Fanouriakis A, Kostopoulou M, Andersen J et al. EULAR recommendations for the management of systemic lupus erythematosus: 2023 update. Ann Rheum Dis. 2023 Oct 12:ard-2023-224762.
日本リウマチ学会編:全身性エリテマトーデス診療ガイドライン2019
Mathian A, Pha M, Haroche J et al. Withdrawal of low-dose prednisone in SLE patients with a clinically quiescent disease for more than 1 year: a randomised clinical trial. Ann Rheum Dis. 2020 Mar;79(3):339-346.
Dooley MA, Jayne D, Ginzler EM, Isenberg D, Olsen NJ, Wofsy D, Eitner F, Appel GB, Contreras G, Lisk L, Solomons N; ALMS Group. Mycophenolate versus azathioprine as maintenance therapy for lupus nephritis. N Engl J Med. 2011 Nov 17;365(20):1886-95.
Houssiau FA, D'Cruz D, Sangle S et al. Azathioprine versus mycophenolate mofetil for long-term immunosuppression in lupus nephritis: results from the MAINTAIN Nephritis Trial. Ann Rheum Dis. 2010 Dec;69(12):2083-9.
Urowitz MB, Gladman DD, Ibañez D et al. Effect of Disease Activity on Organ Damage Progression in Systemic Lupus Erythematosus: University of Toronto Lupus Clinic Cohort. J Rheumatol. 2021 Jan 1;48(1):67-73.
Elera-Fitzcarrald C, Alva M, Gamboa-Cardenas R et al. Factors associated with health-related quality of life in Peruvian patients with systemic lupus erythematosus. Lupus. 2018 May;27(6):913-919.
Hochberg MC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum. 1997 Sep;40(9):1725.
Weening JJ, D'Agati VD, Schwartz MM et al. The classification of glomerulonephritis in systemic lupus erythematosus revisited. Kidney Int. 2004 Feb;65(2):521-30.
Gordon C, Jayne D, Pusey C, et al. European consensus statement on the terminology used in the management of lupus glomerulonephritis. Lupus. 2009 Mar;18(3):257-63.
Erselcan T, Hasbek Z, Tandogan I, et al. Modification of Diet in Renal Disease equation in the risk stratification of contrast induced acute kidney injury in hospital inpatients. Nefrologia. 2009;29(5):397-403.
手良向 聡, 臨床試験におけるランダム化の意義と限界, 計量生物学, 2020-2021, 41 巻, 1 号, p. 37-54.
Petri M, Kim MY, Kalunian KC et al. Combined oral contraceptives in women with systemic lupus erythematosus. N Engl J Med. 2005 Dec 15;353(24):2550-8.
Piaggio G, Elbourne DR, Pocock SJ, et al. Reporting of noninferiority and equivalence randomized trials: extension of the CONSORT 2010 statement. JAMA. 2012 Dec 26;308(24):2594-604.
プラケニル®︎錠 200mg 添付文書
Fukuhara S, Bito S, Green J, et al. J Clin Epidemiol. 1998 Nov;51(11):1037-44.
Elera-Fitzcarrald C, Alva M, Gamboa-Cardenas R et al. Factors associated with health-related quality of life in Peruvian patients with systemic lupus erythematosus. Lupus. 2018 May;27(6):913-919.
Jourde-Chiche N, Chiche L, Mancini J, et al. Proliferative lupus nephritis treatment: practice survey in nephrology and internal medicine in France. Nephrol Ther. 2014 Jun;10(3):170-6.
Ngamjanyaporn P, McCarthy EM, Sergeant JC, et al. Clinicians approaches to management of background treatment in patients with SLE in clinical remission: results of an international observational survey. Lupus Sci Med. 2017 Jun 29;4(1):e000173.
Bertsias GK, Tektonidou M, Amoura Z, et al. Joint European League Against Rheumatism and European Renal Association-European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of adult and paediatric lupus nephritis. Ann Rheum Dis. 2012 Nov;71(11):1771-82.
吉田 雅博, 診療ガイドライン推奨作成のための合意形成法―Delphi法についての調査報告―, 東京女子医科大学雑誌, 2018, 88 巻, Extra1 号, p. E35-E37.
Cattran, D. C., Feehally, J., Cook, H. et al. Kidney disease: Improving global outcomes (KDIGO) glomerulonephritis work group. KDIGO clinical practice guideline for glomerulonephritis. Kidney International Supplements, 2(2), 139-274.
松下 功, 診療ガイドライン作成におけるGRADEシステム, 臨床リウマチ, 2020, 32 巻, 3 号, p. 177-180.
Hahn BH, McMahon MA, Wilkinson A, et al. American College of Rheumatology guidelines for screening, treatment, and management of lupus nephritis. Arthritis Care Res (Hoboken). 2012 Jun;64(6):797-808.
Fanouriakis A, Kostopoulou M, Cheema K, et al. 2019 Update of the Joint European League Against Rheumatism and European Renal Association-European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of lupus nephritis. Ann Rheum Dis. 2020 Jun;79(6):713-723.
Jourde-Chiche N, Costedoat-Chalumeau N, Baumstarck K, et al. Weaning of maintenance immunosuppressive therapy in lupus nephritis (WIN-Lupus): results of a multicentre randomised controlled trial. Ann Rheum Dis. 2022 Oct;81(10):1420-1427.
Moroni G, Longhi S, Giglio E, et al. What happens after complete withdrawal of therapy in patients with lupus nephritis. Clin Exp Rheumatol. 2013 Jul-Aug;31(4 Suppl 78):S75-81.
De Rosa M, Azzato F, Toblli JE, et al. A prospective observational cohort study highlights kidney biopsy findings of lupus nephritis patients in remission who flare following withdrawal of maintenance therapy. Kidney Int. 2018 Oct;94(4):788-794.
Malvar A, Pirruccio P, Alberton V, et al. Histologic versus clinical remission in proliferative lupus nephritis. Nephrol Dial Transplant. 2017 Aug 1;32(8):1338-1344.
Zen M, Fuzzi E, Loredo Martinez M, et al A. Immunosuppressive therapy withdrawal after remission achievement in patients with lupus nephritis. Rheumatology (Oxford). 2022 Feb 2;61(2):688-695.
GOLDER, Vera, et al. Lupus low disease activity state as a treatment endpoint for systemic lupus erythematosus: a prospective validation study. The Lancet Rheumatology, 2019, 1.2: e95-e102.
